Promotions & Moves

Recipharm Appoints New Business Directors

Boselli and Pluta to head sales in Italy and France

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm has appointed a new business director for the Italian pharmaceutical market and a new general manager in Pessac, France. Franco Boselli will serve as business director in Italy selling Recipharm’s full service offering to Italian pharmaceutical companies. He reports to vice president of business management, Kenth Berg, and is based in Milan.
 
Prior to joining the company, Mr. Boselli worked in marketing and sales at several pharmaceutical companies in Italy. In 2009, he served as business development manager at Mipharm, an Italian CMO specializing in non-sterile products. In 2011, he joined Biologici Italia Laboratories as business development director, which later became part of the Corvette group, acquired by Recipharm last year. In this role, he was responsible for new business, including the out-licensing of dossiers of sterile injectables and the development of new dossiers for generic products as well as sales of contract manufacturing of lyophilized and sterile formulations.
 
Bernard Pluta was named general manager for the operating company in Pessac, France and will report to executive vice president of development and technology, Carl-Johan Spak. Mr. Pluta has held executive positions in Theramex and Teva and currently runs his own CMO consultancy business. Mr. Pluta will work to drive sales of new projects and operational excellence.  
 
Thomas Eldered, chief executive officer of Recipharm said, “I am delighted that Mr. Boselli and Mr. Pluta have joined Recipharm. Both bring great skills and experience to our organization. Mr. Boselli’s knowledge and expertise will be invaluable to the continuing growth and expansion of our Italian business across the whole Recipharm network. Mr. Pluta’s industry expertise and solid business competence will play a key role in the task at hand to increase performance at Recipharm Pessac whilst maintaining the highest quality standards of service.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters